Ipsen has entered into an exclusive licensing agreement with Simcere Zaiming for SIM0613, which is a preclinical antibody drug compound (ADC) targeting the LRRC15 protein.1][3][4] The agreement provides Ipsen with global rights to develop, manufacture and commercialize outside of Greater China.[4]Simcere Zaiming may receive up to $1.06 billion in total, including upfront subscription payments, milestone payments for development, regulatory and commercial success, and tiered royalties on sales.[1][2][3][4] SIM0613 is designed for better tumor penetration and distinct anti-tumor activity in solid tumors with the greatest unmet need.The drug has shown robust tumor regression in multiple preclinical models in vivo.1][3][4] Ipsen will assume responsibility for all activities outside of Greater China, including preparation for Phase I clinical trials and submission of Investigational New Drug applications.[1][2][3] The SIM0613 program is expected to enter Phase I clinical development in the second half of 2026.[1][3][4] Ipsen's pipeline is expected to enter Phase I clinical development in the second half of 2026.